-+ 0.00%
-+ 0.00%
-+ 0.00%

Yasheng Pharmaceutical announced that the company's two original Class 1 new drugs were successfully included in the new “National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue”, respectively: Resentul® was first included in the national medical insurance drug catalogue through negotiations for adult chronic lymphocytic leukemia/small lymphocytic lymphoma patients who have previously undergone a system treatment including at least Bruton's tyrosine kinase inhibitors. Nellick® successfully renewed the national health insurance drug catalogue through renegotiation for 1. Adult patients with chronic myeloid leukemia resistant and/or intolerant to first-generation and second-generation tyrosine kinase inhibitors; and 2. Adult patients with CML-CP or accelerated phase T315I mutations. Up to now, all approved indications for Yasheng Pharmaceutical's two innovative drugs have been included in the national medical insurance drug catalogue, which will provide more patients with more accessible innovative treatment options. The new version of the National Medical Insurance Drug Catalogue will be officially implemented on January 1, 2027.

Zhitongcaijing·11/15/2026 23:33:32
Listen to the news
Yasheng Pharmaceutical announced that the company's two original Class 1 new drugs were successfully included in the new “National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue”, respectively: Resentul® was first included in the national medical insurance drug catalogue through negotiations for adult chronic lymphocytic leukemia/small lymphocytic lymphoma patients who have previously undergone a system treatment including at least Bruton's tyrosine kinase inhibitors. Nellick® successfully renewed the national health insurance drug catalogue through renegotiation for 1. Adult patients with chronic myeloid leukemia resistant and/or intolerant to first-generation and second-generation tyrosine kinase inhibitors; and 2. Adult patients with CML-CP or accelerated phase T315I mutations. Up to now, all approved indications for Yasheng Pharmaceutical's two innovative drugs have been included in the national medical insurance drug catalogue, which will provide more patients with more accessible innovative treatment options. The new version of the National Medical Insurance Drug Catalogue will be officially implemented on January 1, 2027.